Journal ArticleDOI
Mesenchymal stem cells in chemotherapy-induced peripheral neuropathy: A new challenging approach that requires further investigations
TLDR
MSCs‐based therapies may provide a new therapeutic strategy for patients suffering from CIPN where further investigations are required for studying their exact mechanisms and combined therapy with pharmacological agents can provide another promising option for enhancing MSC therapy success while limiting its adverse effects.Abstract:
Chemotherapeutic drugs may disrupt the nervous system and cause chemotherapy-induced peripheral neuropathy (CIPN) as side effects. There are no completely successful medications for the prevention or treatment of CIPN. Many drugs such as tricyclic antidepressants and anticonvulsants have been used for symptomatic treatment of CIPN. Unfortunately, these drugs often give only partial relief or have dose-limiting side effects. Thus, the treatment of CIPN becomes a challenge because of failure to regenerate and repair the injured neurons. Mesenchymal stem cell (MSC) therapy is a new attractive approach for CIPN. Evidence has demonstrated that MSCs play important roles in reducing oxidative stress, neuroinflammation, and apoptosis, as well as mediating axon regeneration after nerve damage in several experimental studies and some clinical trials. We will briefly review the pathogenesis of CIPN, traditional therapies used and their drawbacks as well as therapeutic effects of MSCs, their related mechanisms, future challenges for their clinical application, and the additional benefit of their combination with pharmacological agents. MSCs-based therapies may provide a new therapeutic strategy for patients suffering from CIPN where further investigations are required for studying their exact mechanisms. Combined therapy with pharmacological agents can provide another promising option for enhancing MSC therapy success while limiting its adverse effects.read more
Citations
More filters
Journal ArticleDOI
Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity
TL;DR: The present article summarizes the most recent advances in the field of studies on CIPN caused by oxaliplatin, the third-generation platinum-based antitumor drug used to treat colorectal cancer.
Journal ArticleDOI
Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development
TL;DR: In this article, the authors summarized the most recent advances in the field of studies on OIPN, the overview of the clinical syndrome, molecular basis, therapy development, and outlook of future drug candidates.
Journal ArticleDOI
Reestablishment of Redox Homeostasis in the Nociceptive Primary Afferent as a Mechanism of Antinociception Promoted by Mesenchymal Stem/Stromal Cells in Oxaliplatin-Induced Chronic Peripheral Neuropathy.
Anna Lethícia Lima Oliveira,Gisele Graça Leite dos Santos,Renan Fernandes do Espírito-Santo,Gessica Sabrina de Assis Silva,Afrânio Ferreira Evangelista,Daniela Nascimento Silva,Milena Botelho Pereira Soares,Milena Botelho Pereira Soares,Milena Botelho Pereira Soares,Cristiane Flora Villarreal,Cristiane Flora Villarreal +10 more
TL;DR: In this article, the mesenchymal stem/stromal cells (MSC) were transplanted in mice with OXL-induced peripheral neuropathy and showed an antinociceptive effect.
Journal ArticleDOI
The Effect of Schwann Cells/Schwann Cell-Like Cells on Cell Therapy for Peripheral Neuropathy
Zhongya Wei,Rien H L Hoge +1 more
TL;DR: In this article , the authors summarize the literature regarding the use of Schwann cell/Schwann cell-like cell transplantation for different peripheral neuropathies and the potential role of promoting nerve repair and functional recovery.
Journal ArticleDOI
Transplantation of IFN-γ Primed hUCMSCs Significantly Improved Outcomes of Experimental Autoimmune Encephalomyelitis in a Mouse Model.
Xiaoyan Zhou,Xiaoli Liu,Xiaoli Liu,Li Liu,Chao Han,Zhaohong Xie,Xiangtian Liu,Yingying Xu,Fan Li,Jianzhong Bi,Chengyun Zheng,Chengyun Zheng +11 more
TL;DR: Results showed that IFN-γ could up-regulate protein expression of indoleamine 2, 3-dioxygenease 1 (IDO1), an important molecule released by MSCs to exert their immune suppressive activity, and highlight a great clinical potential of IFn-γ-hUCMSCs for multiple sclerosis (MS) treatment.
References
More filters
Journal ArticleDOI
Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.
TL;DR: Both UCB and AT are attractive alternatives to BM in isolating MSC: AT as it contains MSCs at the highest frequency and UCB as it seems to be expandable to higher numbers.
Journal ArticleDOI
Adult rat and human bone marrow stromal cells differentiate into neurons
TL;DR: Adult marrow stromal cells can be induced to overcome their mesenchymal commitment and may constitute an abundant and accessible cellular reservoir for the treatment of a variety of neurologic diseases.
Journal ArticleDOI
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
Nanna B. Finnerup,Nadine Attal,Simon Haroutounian,Ewan D McNicol,Ralf Baron,Robert H. Dworkin,Ian Gilron,Maija Haanpää,Per Hansson,Per Hansson,Troels S. Jensen,Troels S. Jensen,Peter R. Kamerman,Karen Lund,Andrew Moore,Srinivasa N. Raja,Andrew S.C. Rice,Andrew S.C. Rice,Michael C. Rowbotham,Emily S. Sena,Emily S. Sena,Philip J. Siddall,Philip J. Siddall,Blair H. Smith,Mark S. Wallace +24 more
TL;DR: The results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain and allow a strong recommendation for use and proposal as first-line treatment in neuropathicPain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin.
Journal ArticleDOI
Pharmacologic management of neuropathic pain: evidence-based recommendations.
Robert H. Dworkin,Alec B. O'Connor,Miroslav Backonja,John T. Farrar,Nanna B. Finnerup,Troels S. Jensen,Eija Kalso,John D. Loeser,Christine Miaskowski,Turo Nurmikko,Russell K. Portenoy,Andrew S.C. Rice,Brett R. Stacey,Rolf-Detlef Treede,Dennis C. Turk,Mark S. Wallace +15 more
TL;DR: Patients with neuropathic pain are challenging to manage and evidence‐based clinical recommendations for pharmacologic management are needed, and medications should be individualized, considering side effects, potential beneficial or deleterious effects on comorbidities, and whether prompt onset of pain relief is necessary.
Journal ArticleDOI
Algorithm for neuropathic pain treatment:: an evidence based proposal.
TL;DR: NNT and NNH are currently the best way to assess relative efficacy and safety, but the need for dichotomous data, which may have to be estimated retrospectively for old trials, and the methodological complexity of pooling data from small cross‐over and large parallel group trials, remain as limitations.
Related Papers (5)
Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus
Bárbara Soria-Juan,Natalia Escacena,Vivian Capilla-Gonzalez,Yolanda Aguilera,Lucía Llanos,Juan R. Tejedo,Francisco J. Bedoya,Verónica Juan,Antonio De la Cuesta,Rafael Ruiz-Salmerón,Enrique J. Andreu,Lukas Grochowicz,Felipe Prosper,Fermín Sánchez-Guijo,Francisco Lozano,Manuel Miralles,Lourdes Del Río-Solá,Gregorio Castellanos,José M. Moraleda,Robert Sackstein,Mariano García-Arranz,Damián García-Olmo,Franz Martín,Abdelkrim Hmadcha,Bernat Soria +24 more